WHO ICTRP trial
Use of Celecoxib (a pain-relief and anti-inflammatory medicine) along with…
CTRI/2025/08/093611 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/08/093611 |
|---|---|
| Public title | Use of Celecoxib (a pain-relief and anti-inflammatory medicine) along with standard treatment in patients with first-episode schizophrenia: A study on its effect on symptoms and body chemicals related to inflammation |
| Scientific title | Celecoxib augmentation in patients with first episode schizophrenia and its correlation with Indoleamine 2,3-dioxygenase, Interferon-gamma, and Tumor Necrosis Factor-alpha: An open label case control study - NIL |
| Primary sponsor | Central Institute Of Psychiatry |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: F20- Schizophrenia |
| Interventions | Intervention1: Celecoxib Augmentation: Tablet Celecoxib 400mg/day orally for 6 weeks in first episode of schizophrenia along with Antipsychotics Control Intervention1: NIL: NIL |
| Registration date | Aug 25, 2025 |
| Target size | 75 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: